Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168730 | 0.88 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| Ammonia Solution, Strong SCHEMBL28166385 | 0.86 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| Methoxymethane SCHEMBL28184894 | 0.86 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL18120860 | 0.85 | LMNA (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL17933645 | 0.85 | TSHR (0.37) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1812866 | 0.82 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL14849447 | 0.80 | MGAM (0.44) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL23330 | 0.80 | ALDH1A1 (0.44) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL13399022 | 0.77 | USP2 (0.36) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL28483049 | 0.77 | DGAT1 (0.45) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737461-B2 | Citrate perhydrates and uses thereof | BIOREM ENGINEERING SA (CH) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737461-B2 | Citrate perhydrates and uses thereof | CS, HAGH, HOGA1 | TSHR 2990/4885HSD17B10 41/4885MGAM 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.